Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD : A Randomized Controlled Double‐Blind Phase 2 Trial-Reference-Cited by-同舟云学术

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD : A Randomized Controlled Double‐Blind Phase 2 Trial

Published:2021-07-19 Issue:4 Volume:74 Page:1809-1824
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Gawrieh Samer¹^ORCID,Noureddin Mazen²,Loo Nicole³,Mohseni Rizwana⁴,Awasty Vivek⁵,Cusi Kenneth⁶,Kowdley Kris V.⁷^ORCID,Lai Michelle⁸,Schiff Eugene⁹,Parmar Deven¹⁰,Patel Pankaj¹¹,Chalasani Naga¹^ORCID

Affiliation:

1. Gastroenterology & Hepatology Indiana University School of Medicine Indianapolis IN

2. Digestive and Liver Diseases Cedars Sinai Medical Center Los Angeles CA

3. Hepatobiliary CancerTexas Liver Institute San Antonio TX

4. Catalina Research Institute, LLC Montclair CA

5. Internal Medicine Ohio health Marion General Hospital Marion OH

6. Endocrinology Diabetes & Metabolism University of Florida Gainesville FL

7. Liver Institute Northwest Seattle WA

8. Gastroenterology and Hepatology Beth Israel Deaconess Medical Center Boston MA

9. Schiff Center for Liver Diseases University of Miami School of Medicine Miami FL

10. Zydus Discovery DMCC Dubai UAE

11. Zydus Research CentreCadila Healthcare Ltd. Ahmedabad India

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31843

Reference45 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

3. Nonalcoholic Fatty Liver Disease

4. Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

5. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors;Pharmacological Research;2024-10

3. Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?;Digestive and Liver Disease;2024-09

4. Apigenin-6-C-glucoside ameliorates MASLD in rodent models via selective agonism of adiponectin receptor 2;European Journal of Pharmacology;2024-09

5. Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH;Journal of Clinical and Experimental Hepatology;2024-09